Q-omics provides the consensus-scored TUBAP14 profile across patient tissues and cancer cell-line models. TUBAP14 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, TUBAP14 is differentially expressed in 5, with the highest sampling consensus in KIRC. Additionally, TUBAP14 RNA expression shows 11,134 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, KIRC, and ACC as cancer lineages where TUBAP14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TUBAP14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TUBAP14 survival associations across molecular data types. TUBAP14 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TUBAP14 RNA expression–survival associations across cancer types. High TUBAP14 expression shows unfavorable associations in MESO, LGG, ACC, SARC and KICH, but favorable associations in UCS. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for TUBAP14 RNA expression.
This table summarizes TUBAP14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TUBAP14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TUBAP14 shows lower tumor expression in READ and higher tumor expression in KIRC, HNSC, KIRP and BRCA. The KIRC box plot shows higher TUBAP14 RNA expression in tumor versus normal tissue (log2 FC = +0.120, t-test p < 0.001).
This table shows molecular features associated with TUBAP14 in patient tissues and cancer cell lines. In patient samples, TUBAP14 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
